Definium Therapeutics
(NASDAQ) DFTX
Definium Therapeutics Financials at a Glance
Market Cap
$6.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$237.54M
EPS (TTM)
-$2.50
P/E Ratio
-18.80
Dividend
$0.00
Beta (Volatility)
1.52 (High)
Dividend
$0.00
Beta (Volatility)
1.52 (High)
Price
$47.02
Volume
2,556,088.564
Open
$47.73
Price
$47.02
Volume
2,556,088.564
Open
$47.73
Previous Close
$47.07
Daily Range
$44.52 - $48.39
52-Week Range
$7.96 - $49.20
Estimated Earnings Date
N/A
Dividend
$0.00
Beta (Volatility)
1.52 (High)
Price
$47.02
Volume
2,556,088.564
Open
$47.73
Previous Close
$47.07
Daily Range
$44.52 - $48.39
52-Week Range
$7.96 - $49.20
Estimated Earnings Date
N/A
DFTX News
DFTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Definium Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
106
CEO
Robert Barrow, CFA
Website
www.mindmed.coHeadquarters
New York, NY 10007, US
DFTX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-102.48%
Return on Capital
-50.04%
Return on Assets
-59.19%
Earnings Yield
-5.32%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$6.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
132.74M
Volume
2.56M
Avg. Volume
2.92M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$193.37M
EBITDA
-$222.35M
Operating Cash Flow
-$143.69M
Capital Expenditure
$0.00
Free Cash Flow
-$143.69M
Cash & ST Invst.
$373.42M
Total Debt
$0.00
Definium Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$6.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$58.95M
N/A
Employees
106
N/A
Net Income
-$77.10M
-230.2%
EBITDA
-$75.22M
-230.7%
Quarterly Fundamentals
Total Cash
$373.42M
+75.8%
Total Debt
$0.00
-100.0%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
N/A
Return on Assets
-59.19%
N/A
Return on Invested Capital
-60.39%
N/A
Free Cash Flow
-$42.63M
-44.9%
Operating Cash Flow
-$42.63M
-44.9%